Page 146 - CW E-Magazine (19-8-2025)

Pharmaceuticals

FOCUSSED SUPPLY CHAIN
Celcius launches specialised logistics arm for pharma

sector

Celcius Logistics, a third-party logis- trol, compliance and real-time visibility, tics, operations and regulatory compli-
tics and cold supply chain solutions pro- Celcius+ ensures medicines, vaccines and ance. “With this new vertical, we plan
vider, has launched a specialised logistics other sensitive products are transported to partner with leading pharmaceutical
arm for pharmaceutical supply chain, with maximum safety and effi ciency, he companies and extend its reach to more
Celcius+. informed. than 100 cities across India by the end of
2025,” Mr. Bose added.
“Our investment in this vertical marks In its initial phase, Celcius will invest
the beginning of a focused journey to Rs. 50-crore to create a dedicated pharma Celcius+ will deliver tech-enabled
bridge gaps in pharma distribution with fl eet and support infrastructure, with a supply chain solutions tailored for
tech-backed, Good Distribution Practice goal of achieving Rs. 100-crore in Annual pharmaceutical and healthcare clients,
(GDP)-compliant solutions,” said Mr. Recurring Revenue (ARR) from this addressing critical challenges such as
Swarup Bose, founder and CEO, Celcius segment within the next 18 months. temperature-sensitive logistics, regulatory
Logistics. adherence and real-time shipment visibi-
Of this, Rs. 35-crore will be allocated lity. The vertical will focus on high-value,
“This initiative is in line with Celcius towards deploying 100 new reefer sensitive segments including vaccines,
Logistics’ mission to bridge cold chain vehicles for Celcius+ along key pharma- biologics, insulin and specialty medicines,
gaps, reduce wastage and enable safe, ceutical corridors across India. A further off ering services that span primary distri-
timely deliveries for life-saving products. Rs. 10-15 crore is being earmarked to build bution, secondary distribution and last-
We’re confi dent that Celcius+ will help a robust pharma courier system tailored mile pharma courier delivery.
pharmaceutical companies extend their to serve high-demand urban and semi-
reach safely and effi ciently across major urban markets, Mr. Bose said. Earlier this year, Celcius Logistics
cities by year-end,” he added. raised Rs. 250-crore in an oversub-
To support this rapid expansion, scribed Series B funding round to accele-
Designed to meet the sector’s strin- Celcius will add 30-40 specialised team rate technology upgrades and network
gent requirements for temperature con- members with expertise in pharma logis- expansion.
COLLABORATION
Lupin partners with Sandoz to commercialise

ranibizumab in different markets

Lupin has partnered with Swiss Vietnam, and Malaysia; while Sandoz will acquire
major Sandoz Group AG to market and Lupin will be responsible for sole rights for commer-
commercialise Lupin’s biosimilar rani- manufacturing the product and cialisation of Lupin’s
bizumab across multiple regions. The for regulatory submissions, biosimilar ranibizumab
drug is indicated to treat Neovascular Lupin said in a press note. in Canada, while Lupin
(Wet) Age-Related Macular Degene- will manage its manu-
ration (AMD), Diabetic Macular Edema Sandoz will hold exclusive facture and regulatory
and Proliferative Diabetic Retinopathy, marketing rights in most of the designated fi lings,” it added.
among other conditions. markets, except for France, Australia,
Vietnam, and Malaysia, where it will Ranibizumab is a recombinant
Sandoz will oversee commerciali- have semi-exclusive marketing rights. humanised IgG1 monoclonal anti-
sation of the product across the European body fragment that binds to and inhib-
Union (excluding Germany), Switzer- “Pursuant to another agreement exe- its vascular endothelial growth factor A
land, Norway, Australia, Hong Kong, cuted between the two companies, (VEGF-A), the note explained.

146 Chemical Weekly August 19, 2025

Contents Index to Advertisers Index to Products Advertised